Drug Profile
TPC 806
Alternative Names: TEI-F00806; TPC-806Latest Information Update: 13 Jan 2020
Price :
$50
*
At a glance
- Originator Teijin Pharma
- Class Heart failure therapies
- Mechanism of Action Chymase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Heart failure
Most Recent Events
- 05 Sep 2019 Preclinical pharmacodynamics data in Heart failure presented at the Hypertension Scientific Session (HTN-2019)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Heart-failure in Japan (PO)
- 31 Mar 2009 Phase-II clinical trials in Congestive heart failure in Japan (PO)